PlacMr. Veitch will report directly to Mr. John H. Johnson, Chief Executive Officer and President of Savient and will be responsible for establishing, building and leading Savient's European regional organization to launch and drive the future growth of KRYSTEXXA®.
"I am pleased to welcome David to the Savient team as head of our European operations," said Mr. Johnson. "David has spent more than twenty years in critical pharmaceutical leadership positions within the European markets and has a track record of successfully launching specialty products in Europe. David will be a critical member of our team as we launch KRYSTEXXA in Europe and achieve our goal of bringing relief to patients suffering from refractory chronic gout in Europe, where there are currently no EMA approved treatments for refractory chronic gout available. We believe there is a clear unmet need for new therapies to treat patients suffering from this debilitating disease and expect KRYSTEXXA will have an important role in the future management of refractory chronic gout globally."
As previously announced, in May 2011 Savient submitted its European Marketing Authorization Application (MAA) for KRYSTEXXA, and anticipates European Union approval in the second half of 2012. The Company expects KRYSTEXXA to be available in the European Union on a named patient basis by the end of the first quarter of 2012. Savient has engaged regional medical scientists for its European region and has reimbursement plans and KOL engagement underway.